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Objective: To investigate the relationship between placental transthyretin (TTR) level and preeclampsia.
Materials and Methods: Placental tissues from uncomplicated and preeclamptic pregnancies were
analyzed using immunohistochemistry and image analysis. We measured the mean optical density (OD)
of immunohistochemical staining of TTR across multiple sections using Image Pro Plus 6.0. To avoid bias,
we used placental tissue array, which contained preeclamptic placentas (n ¼ 8) and the control placentas
(n ¼ 6) on the same slide.
Results: The mean TTR OD of the syncytiotrophoblast layer of placentas (95% conﬁdence interval) from
the ﬁrst trimester was higher than those from the second/third trimester, and term placentas [0.149
(0.014e0.285) for the 1st trimester, 0.037 (0.000e0.073) for the 2nd/3rd trimester, and 0.011 (0.035
e0.056) for term; p < 0.01]. Although the OD of the second/third trimester placentas appeared greater
than that of term placentas, this was not statistically signiﬁcant. The mean TTR OD of the syncytio-
trophoblast layer of the severe preeclampsia group was lower than that of controls [0.010 (0.005e0.016)
vs. 0.027 (0.013e0.041), p < 0.05].
Conclusion: The immunohistochemical expression of TTR in the syncytiotrophoblast layer of the placenta
decreased signiﬁcantly after 12 weeks of gestation, paralleling the changing demands of thyroid hor-
mone uptake into the placenta. The reduced TTR expression in the syncytiotrophoblast layer of the
preeclamptic placenta might impair thyroid hormone uptake and contribute to the pathophysiology of
the disease.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Preeclampsia (PE) is an idiopathic multisystem disorder char-
acterized by new-onset hypertension and proteinuria after 20
weeks of gestation. It is the leading cause of maternal and perinatal
morbidity and mortality [1]. The pathophysiology underlying PE is
still incompletely understood, although it is widely accepted to
involve a failure of appropriate placental development [2]. Differ-
ential gene and protein expression [3], or initial low oxygen envi-
ronment [2] can cause abnormal growth of placenta and fetus [4].Centre for Women's and In-
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bstetrics & Gynecology. Published bNevertheless, the precise cause of the pathological changes within
the placenta prior to the onset of PE is still unclear.
The critical role of thyroid hormones (THs) in the development
of many organs is well recognized. Hypothyroidism may cause
infertility, increased risk of miscarriage, and other obstetric com-
plications including PE [5,6]. Transthyretin (TTR), also known as
prealbumin, is a TH carrier, and it has been suggested that TTR
might inﬂuence the proliferation and differentiation of placental
trophoblast through regulating exposure of placental cells to TH [7].
As a carrier protein, TTR transports multiple molecules, including
THs and retinol. Elevated levels of TTR have been reported in the
amniotic ﬂuid of fetuses with abnormal karyotypes, including tri-
somy 21 and trisomy 18 [8]. In serum, TTR levels decrease after 12
weeks of gestation [9], similar to the changing demands of TH of
fetus. In the placenta, TTR seems to be constant after 13 weeks of
gestation [10]; however, the increased expression of TTR in the
matrix and vessels within the placenta after 13 weeks suggests thaty Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
Table 1
Characteristics of the severe PE and control groups.
sPE Controls
n 8 6
Gestational age (wk) 29 ± 1.7 31 ± 2.4
Gravidity 1.4 ± 0.5 2.0 ± 1.1
Parity 1.0 ± 0.0 1.5 ± 0.8
Placental weight (g) 281 ± 60 385 ± 91
Birth weight (g) 1046 ± 238 1822 ± 328
sPE ¼ severe preeclampsia.
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regulates TH uptake) should be reduced then.
Several studies compared total TTR levels between severe pre-
eclampsia (sPE) and control placentas and found no correlation
[11,12]. Recognizing TTR’s role as a placental transporter, we aimed
to study its spatial distribution. In this study, we measured TTR
expression and distribution in normal placentas across gestation.
We also compared TTR expression in sPE placentas and gestational
matched controls to investigate the possible relationship between
PE and placenta TTR.
Materials and methods
Patients
The diagnosis of sPE was based on the criteria of the National
High Blood Pressure Education Program Working Group on high
blood pressure in pregnancy. The criteria included the presence of
high blood pressure of 160/110mmHg on two occasions at least 6
hours apart that occurred after 20 weeks of gestation in women
with previously normal blood pressure, accompanied with pro-
teinuria ( 5 g/24 hours) or proteinuria of  3þ on two random
urine samples collected at least 4 hours apart. None of the patients
had a history of hypertension or renal diseases. The control par-
ticipants were age matched without hypertension or proteinuria or
other pregnancy complications except preterm labor. This study
was conducted in accordancewith the provisions of the Declaration
of Helsinki. This studywas conductedwith approval from the Ethics
Committee of the Research Centre for Women’s and Infant's Health
(RCWIH) Biobank at Mount Sinai Hospital (Mount Sinai Hospital
Research Ethics Board, MSH REB# 04-0018-U). Written informed
consent was obtained from all participants.
We examined TTR expression in normal placentas across
gestation. First trimester placentas (6e12 gestational weeks) were
obtained from elective terminations of pregnancies by dilatation
and curettage. Second trimester and preterm placentas were from
elective termination and from preterm labor patients without other
pregnancy complications. Term placentas were from spontaneous
labor or cesarean delivery.
Placenta immunohistochemistry
All samples were subjected to the same experimental methods.
Brieﬂy, parafﬁn blocks were cut into 4-mm-thick sections. After
dewaxing in xylene and rehydration in graded alcohol, the sections
were heated in 0.1 mol/L sodium citrate buffer (pH 6.0) in a mi-
crowave oven for 10 minutes for antigen retrieval. The slides were
then incubated with 3% hydrogen peroxide in methanol to block
endogenous peroxidase activity. Nonspeciﬁc binding was blocked
by incubation in blocking solution (protein block, serum-free so-
lution; Dako, Carpinteria, CA, USA) for 10 minutes. Subsequently,
the slides were incubated for 1 hour at room temperature with
speciﬁc Anti-Human-Transthyretin antibody (Dako) diluted 1:200;
in the case of the negative controls, the primary antibody was
replaced with phosphate-buffered saline. Slides were then incu-
bated with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit immunoglobulin G (Dako; 1:300 dilution) for 30 minutes at
room temperature. Substrate-chromogen DAB was added to each
slice for 2 minutes, and the reaction was stopped by washing in
excess tap water. Hematoxylin was used as a counterstain.
Western blotting
Placental tissue from 10 sPE patients and six gestational age-
matched controls was homogenized in 250mM sucrose, 10mMHepes/Tris, pH 7.4 buffer containing a protease inhibitor cocktail
(Sigma-Aldrich, St. Louis, MO, USA). Next, 40 mg total protein was
separated in NuPAGE Novex 4e12% Bis/Tris gradient gels (Invi-
trogen, Grand Island, NY, USA) and transferred to a nitrocellulose
membrane (Millipore, Billerica, MA, USA) for 30 minutes. Blotting
was performed by incubation of the membranes with Rabbit anti-
TTR (Dako) antibody (1:1000 dilution) overnight at 4C. Mem-
branes were incubated with the secondary antibody (antirabbit
immunoglobulin G-HRP; 1:3000 in Tris-buffered saline/Tween 20;
Dako) for 30 minutes. Detection of bound antibody was performed
with Pierce chemiluminescent (ECL) kit (Thermo, Waltham, MA,
USA). Levels of proteins were then quantiﬁed using Quantity-One
program (Bio-Rad Laboratories). TTR protein levels were normal-
ized to b-actin.
Placental tissue array
Immunohistochemical (IHC) technique is a qualitative exami-
nation, and its quantitative analysis might be inﬂuenced by many
procedures including tissue selection, parafﬁn blocks section, and
staining. To avoid these biases as much as possible, we used the
method of placental tissue array. Tissue array slides were obtained
from the RCWIH BioBank program of Mount Sinai Hospital, Tor-
onto, Ontario, Canada, in accordance with the policies of the Mount
Sinai Hospital Research Ethics Board (MSH, 10-0128-E). Each of the
tissue array slides contains sections from eight placentas from sPE
patients and six gestational matched preterm labor controls
(Table 1). The placentas used for tissue array were chosen by an
experienced pathologist, and each placenta was sampled from four
separate locations. The tissue array makes it possible to test TTR in
all the placentas at the same time using exactly the same IHC
procedures. All tissues are located randomly on the slides and
coded until the quantitative analysis was completed.
There was no signiﬁcant difference in gestational age, gravidity,
and parity between the sPE group and the control group. For all the
placentas, no fetal growth restriction was diagnosed.
Quantitative analysis
TTR is expressed in both the syncytiotrophoblast layer and the
stroma of the placenta. We used Image Pro Plus version 6.0 (Media
Cybernetics, Bethesda, Maryland, USA) to analyze the digital im-
ages. This method of IHC quantiﬁcation has been used by several
other groups [13,14]. To avoid possible bias in light intensity during
image capture and to ensure the accuracy of measurements, image
brightness was normalized to background levels. All images are
taken at exactly the same conditions using the same microscope
and camera (Olympus DP72, ISO 200, Olympus, Tokyo, Japan). We
selected syncytiotrophoblast layer and stroma separately as area of
interest (AOI) for measurements. Using Image Pro Plus, we changed
the images to grayscale digital images to test total optical density
(OD) and calculate the area of AOI. We then calculated themean OD
using total OD/area of AOI. The mean OD represents the density of
dye staining and reﬂects the content of TTR.
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Datawere transported into SPSS version 13.0 (SPSS Inc., Chicago,
IL, USA), and statistical analysis was performed using t test and one-
way analysis of variance. A p value < 0.05 was considered statisti-
cally signiﬁcant. Data were expressed as mean ± standard devia-
tion. Graphic representation of the data was prepared using
GraphPad Prism 4.0 (GraphPad Software Inc, San Diego, CA, USA).Results
Placenta immunohistochemistry
Six ﬁrst trimester placentas (6e12 weeks of gestation), nine
second/third trimester placentas (12e37 weeks of gestation), and
nine term (37e41 weeks of gestation) placentas were studied.
Within ﬁrst trimester placentas, syncytiotrophoblast cells showed
strong positive staining for TTR whereas there was no staining in
cytotrophoblast cells and stroma. In second/third trimester pla-
centas, TTR staining in syncytiotrophoblast cells became less pos-
itive whereas the stroma became increasingly positive. In term
placentas, TTR staining in syncytiotrophoblast cells was very weak,
whereas endothelial cells, some blood cells, and some stromal cells
become even more positive than second trimester placentas. Thus,
it appears that TTR levels in syncytiotrophoblast cells decreasewith
the increasing gestational agewhereas levels in the stroma increase
(Figure 1).
Quantitative analysis was conducted using Image Pro Plus to
calculate the mean OD of TTR staining. Initial analysis was con-
ducted using the entire placental area (trophoblast layers and
stroma) and showed no differences in TTR levels across gestation.
However, when the analysis was conducted speciﬁcally on theFigure 1. Transthyretin (TTR) expression in placenta across gestation. Black arrows ident
bars ¼ 6 mm. Syncytiotrophoblast TTR staining becomes progressively weaker with advanc
syncytiotrophoblast. (A) Syncytiotrophoblast cells stain strongly positive for TTR in ﬁrst trim
but stroma TTR started to express. (C) Till term, syncytiotrophoblast TTR was quite weak, b
syncytiotrophoblast layer of ﬁrst trimester placenta was much stronger than second/third t
second/third trimester placenta appeared greater than term placenta, this was not statistical
advancing gestation.syncytiotrophoblast layer, the mean OD of ﬁrst trimester, second/
third trimester, and term placentas was 0.149 [95% conﬁdence in-
terval (CI), 0.014e0.285], 0.037 (95% CI, 0.000e0.073), and 0.011
(95% CI, 0.035e0.056), respectively (Figure 1). Analysis of variance
revealed that TTR staining of ﬁrst trimester placenta was much
stronger than that of second/third trimester (p < 0.01) and term
placenta (p < 0.01). Although the OD of second/third trimester
placenta appeared greater than the OD of term placenta, this
observation did not reach statistical signiﬁcance.
Western blotting
TTR is detected in both sPE and age-matched placentas as a
single band at approximately 16kDa, representing the TTR mono-
mer under dissociating condition. There was no difference in the
TTR expression of sPE placentas and controls (Figure 2).
Placenta tissue array
The tissue array slides included placentas from eight PE patients
and six gestational age-matched controls. Each placenta is sampled
from four different locations. After staining, photographs of four
random ﬁelds for each placental section were taken, and the mean
OD of the 56 photographs was calculated. All photographs were
coded before the quantitative analysis was conducted. As with the
routine placental sections described above, when analysis of the
sections included all placental layers (trophoblast and stroma),
there was no difference in TTR expression in sPE and control groups
(Figure 3). But when the syncytiotrophoblast layer was selected for
analysis, the mean OD of the sPE groupwas signiﬁcantly lower than
that of the control group [0.010 (95% CI, 0.005e0.016) vs. 0.027 (95%
CI, 0.013e0.041); p < 0.05].ify syncytiotrophoblast layers and yellow arrows indicate stroma of placentas. Scale
ing gestation. TTR staining in the stroma shows an inverse relationship to that of the
ester placenta. (B) During second trimester, syncytiotrophoblast TTR became weaker,
ut stroma TTR became strong. (D) Quantitative analysis revealed that TTR staining of
rimester (p < 0.01) and term placenta (p < 0.01). Although the optical density (OD) of
ly signiﬁcant. (E) Syncytiotrophoblast TTR staining becomes progressively weaker with
Figure 2. When we directly compared total transthyretin (TTR) in placentas using
Western blotting test, no signiﬁcant difference was found between severe pre-
eclampsia (sPE) placentas and controls.
Figure 3. Transthyretin (TTR) expression in severe preeclampsia (sPE) placentas and controls. Black arrows identify syncytiotrophoblast layers and yellow arrows indicate stroma of
placentas. Scale bars ¼ 6 mm. TTR expression in whole placenta or stroma of sPE patients was not signiﬁcantly different from gestational matched controls, but in syncytio-
trophoblast it was signiﬁcantly reduced compared with controls (p < 0.05).
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PE causes millions of maternal and perinatal deaths every year;
however, the mechanisms underlying its pathophysiology remain
unclear. Our research focused on the TH carrier, TTR.
THs are very important for growth and differentiation of many
organs. Human fetal TH synthesis is initiated at about 12 weeks of
gestation, and thus in the ﬁrst trimester TH needs to be transported
from the maternal circulation across the placental barrier tosupport the fetal development [15]. Even after 12 weeks of gesta-
tion, the fetus still requires additional transport of THs from the
mother [15].
The functional form of TH is T3. The availability of the active
ligand T3 within tissues is locally determined by the action of the
iodothyronine deiodinases. There are three subtypesdD1, D2, and
D3. T3 is generated by the activity of D1 and D2, via 5# reductive or
outer ring deiodination of the prohormone T4 to 3,5,30-triiodo-
thyronine, whereas D3 converts T4 to 3,3,50-triiodothyronine
(reverse T3, rT3), acting as a deactivating enzyme for THs [16]. In
placenta, there is only D2 and D3. T4 is transported into cells, and
deiodinated by D2, and converted to T3 [16].
T3 can act directly on placental tissue and inﬂuence the prolif-
eration and differentiation of trophoblast cells. It enhances the
production of epidermal growth factor (EGF) by trophoblast cells
in vitro [17,18], and the expression of integrins and matrix meta-
lloproteinases (MMPs) in cultured early placental extravillous tro-
phoblasts (EVTs) [18].
The placenta has high levels of D3, which acts as a barrier to
TH uptake. TH thus requires active transporters to enter theplacenta [7,19,20]. The precise mechanism by which T4 is trans-
ported into trophoblast cells is not clear. Certain proteins, such as
members of organic anion-transporting polypeptides, mono-
carboxylate transporter, can transport T4 or T3 across the mem-
brane [21]. TTR plays an important role in TH transportation
[7,22]. Human placenta trophoblast cells can secrete and inter-
nalize TTR, and the internalization is dramatically increased in
the presence of T4 (125I-T4) or T3, which enter cells as a complex
with TTR [22].
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most positive in syncytiotrophoblast cells from the ﬁrst trimester
and decreases with gestational age until term when expression is
very weak or negative. Within the stroma, however, staining
appeared in the second trimester and became stronger with
increasing gestational age. These observations correlate with the
fetal changing demands for TH transport across the placenta. Once
the fetal thyroid gland begins to produce TH, additional TH
transport from the maternal circulation could harm fetal growth
and developmentdconsequently, TTR levels in the trophoblast are
decreased and further reduced till term when the fetal thyroid can
produce all of the required THs. This result differs somewhat from
the study of Patel et al [10], who found that TTR levels increased
to the end of the ﬁrst trimester then remained high until term.
This apparent discrepancy might be attributed to the differential
expression of TTR between the syncytiotrophoblast layer and the
stroma. In the context of a placental transporter, it is more
informative to study TTR expression in the syncytiotrophoblast
layer.
The changing level of TTR expression in the syncytiotrophoblast
across gestation is intriguing. TH can inﬂuence trophoblast prolif-
eration and differentiation as well as contribute to increased
placental trophoblast invasiveness [17,18,23]. The ability of TTR to
aid transport of TH across the placental barrier [7,22] suggests that
this protein may play an important role in normal placental
development especially in the ﬁrst trimester. In a previous study
using proteomic methodology, we found that the TTR serum levels
are greatly reduced in PE patients [24]. Our current study suggests
that TTR expression by syncytiotrophoblast cells might be a
contributing pathway to PE. Our initial examination using Western
blotting showed no difference in TTR levels in the placenta of sPE
patients compared to preterm controls. This is consistent with
other proteomic studies that found no signiﬁcant difference [11] or
even upregulation of TTR [12] in placentas from PE patients. We
questioned whether this might be attributed to TTR synthesized by
other placental cell types or to the fetal circulation entering the
placenta stroma. We therefore investigated the differential
expression of TTR between the syncytiotrophoblast and the stroma.
Our results conﬁrmed that TTR levels are signiﬁcantly reduced in
the syncytiotrophoblast of sPE placentas as compared to age-
matched controls. The total placental expression of TTR (i.e.,
when stromal expression is included) shows no difference between
PE and age-matched controls. These ﬁndings likely explain why
analysis of TTR fromwhole placentas failed to detect differences in
expression in PE and controls.
In summary, we have documented inverse changes in the levels
of TTR in syncytiotrophoblast and stromal compartments of the
placenta across gestation. We have also shown that syncytio-
trophoblast TTR levels, but not the stromal expression, are reduced
in patients with PE compared to patients without PE at a similar
gestational age (preterm birth). The fact that these changes are only
detected when cell layer-speciﬁc analyses are conducted may ac-
count for the failure of previous studies to detect altered placental
TTR levels in association with PE. The consequences of the reduced
level of TTR in the syncytiotrophoblast remains to be determined,
but we speculate that reduced TH transport in the ﬁrst trimester
would impair trophoblast proliferation and differentiation and thatthe compromised placental development might contribute to the
pathogenesis of PE.
Conﬂicts of interest
The authors have no conﬂicts of interest relevant to this article.
References
[1] Sibai B, Dekker G, Kupferminc M. Preeclampsia. Lancet 2005;365:785e99.
[2] Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertens
2012;2:72e83.
[3] Chang SD, Chao AS, Peng HH, Chang YL, Wang CN, Cheng PJ, et al. Analyses of
placental gene expression in pregnancy-related hypertensive disorders.
Taiwan J Obstet Gynecol 2011;50:283e91.
[4] Soong YK, Wang TH, Lee YS, Chen CP, Chang CL, Ho SY, et al. Genome-wide
detection of uniparental disomy in a fetus with intrauterine growth restriction
using genotyping microarrays. Taiwan J Obstet Gynecol 2009;48:152e8.
[5] Leung AM. Thyroid function in pregnancy. J Trace Elem Med Biol 2012;26:
137e40.
[6] Roncaglia N, Avagliano L, Crippa I, Cameroni I, Malberti S, Sala F, et al. Pre-
eclampsia is strongly associated with maternal hypothyroidism. Am J Obstet
Gynecol 2006;195:S109.
[7] Landers KA, Mortimer RH, Richard K. Transthyretin and the human placenta.
Placenta 2013;34:513e7.
[8] Wang TH, Chao AS, Chen JK, Chao A, Chang YL, Cheng PJ, et al. Network an-
alyses of differentially expressed proteins in amniotic ﬂuid supernatant
associated with abnormal human karyotypes. Fertil Steril 2009;92:96e107.
[9] Zhu L, Chen YX, Liu CD, Deng HT, Zhang NW,Wang SD, et al. Transthyretin as a
novel candidate biomarker for preeclampsia. Exp Ther Med 2014;7:1332e6.
[10] Patel J, Landers KA, Li H, Mortimer RH, Richard K. Ontogenic changes in
placental transthyretin. Placenta 2011;32:817e22.
[11] Mine K, Katayama A, Matsumura T, Nishino T, Kuwabara Y, Ishikawa G. Pro-
teome analysis of human placentae: pre-eclampsia versus normal pregnancy.
Placenta 2007;28:676e87.
[12] Gharesi-FardB,Zolghadri J,Kamalli-SarvestaniE.Proteomedifferencesofplacenta
between pre-eclampsia and normal pregnancy. Placenta 2010;31:121e5.
[13] Xavier LL, Viola GG, Ferraz AC, Cunha CD, Deonizio JMD, Netto CA, et al.
A simple and fast densitometric method for the analysis of tyrosine hydrox-
ylase immunoreactivity in the substantia nigra pars compacta and in the
ventral tegmental area. Brain Res Brain Res Protoc 2005;16:58e64.
[14] Samaroo HD, Opsahl AC, Schreiber J, O'Neill SM, Marconi M, Qian J. High
throughput object-based image analysis of b-amyloid plaques in human and
transgenic mouse brain. J Neurosci Methods 2012;204:179e88.
[15] Kilby MD, Barber K, Hobbs E, Franklyn JA. Thyroid hormone action in the
placenta. Placenta 2005;26:105e13.
[16] Kohrle J. Local activation and inactivation of thyroid hormones: the deiodi-
nase family. Mol Cell Endocrinol 1999;151:103e19.
[17] Mauro T, Matsuo H, Otani T, Mochizuki M. Epidermal growth factor (EGF)
regulates trophoblast proliferation and endocrine function in synergy with
thyroid hormone: a review. Trophoblast Res 1997;9:27e39.
[18] Barber KJ, Franklyn JA, Mccabe CJ. The in vitro effects of triiodothyronine on
epidermal growth factor-induced trophoblast function. J Clin Endocrinol
Metab 2005;90:1655e61.
[19] Chan S, Kachilele S, Hobbs E, Bulmer JN, Boelaert K, McCabe CJ, et al. Placental
iodothyronine deiodinase expression in normal and growth-restricted human
pregnancies. J Clin Endocrinol Metab 2003;88:4488e95.
[20] Mortimer RH, Galligan JP, Cannell GR, Addison RS, Roberts MS. Maternal to
fetal thyroxine transmission in the human term placenta is limited by inner
ring deiodination. J Clin Endocrinol Metab 1996;81:2247e9.
[21] Sally RJ, Franklyn JA, Kilby MD. Placental transport of thyroid hormone. Best
Pract Res Clin Endocrinol Metab 2007;21:253e64.
[22] Landers KA, McKinnon BD, Li H, Subramaniam N, Mortimer RH, Richard K.
Carrier-mediated thyroid hormone transport into placenta by placental
transthyretin. J Clin Endocrinol Metab 2009;94:2610e6.
[23] Oki N, Matsuo H, Nakago S, Murakoshi H, Laoag-Fernandez JB, Maruo T. Effects
of 3,5,30-Triiodothyronine on the invasive potential and the expression of
integrins and matrix metalloproteinases in cultured early placental extra-
villous trophoblasts. J Clin Endocrinol Metab 2004;89:5213e21.
[24] Liu C, Zhang N, Yu H, Chen Y, Liang Y, Deng H, et al. Proteomic analysis of
human serum for Finding pathogenic factors and potential biomarkers in
preeclampsia. Placenta 2011;32:168e74.
